Safety and Efficacy of CD19 CAR T-Cells Manufactured Post First HSCT and Administered Following a Second HSCT from a Different 10/10 HLA Matched Unrelated Donor to a Child with Multiple Relapsed B-ALL. | Synapse
March 3, 2026
Safety and Efficacy of CD19 CAR T-Cells Manufactured Post First HSCT and Administered Following a Second HSCT from a Different 10/10 HLA Matched Unrelated Donor to a Child with Multiple Relapsed B-ALL.
Key Points
CD19 CAR T-cells led to notable improvements in disease management outcomes.
The analysis highlights positive responses in a child with multiple relapsed B-ALL after treatment.
Assessment involved interventions with HSCT from a different 10/10 HLA matched donor.
Implications support further investigations into CAR T-cell therapies for pediatric cancers.